A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Novartis

Status: Completed

Conditions: Somatostatin Receptor-positive GEP-NET

Treatments: Other: Lutathera

Study type: Observational

Funder types: Industry

Identifiers

NCT04946305

CAAA601A12403

Details and patient eligibility

About

This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.

Enrollment: 89 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients who start Lutathera treatment per clinical judgment, according to the locally approved labeling.

   • somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.

2. Patients who are willing to provide written informed consent.

Exclusion criteria

1. Patients with contraindication according to prescribing information for Lutathera in Korea.

Trial design

89 participants in 1 patient group

Lutathera

Description:

Patients administered Lutathera by prescription

Treatment:

Other: Lutathera